The European Commission has approved the use of Tecfidera (dimethyl fumarate/BG-12) as a first-line oral treatment for people with relapsing remitting Multiple Sclerosis (RRMS).
The new treatment will be available in Ireland later in 2014 and we will provide a detailed update of its availability as soon as we know more.
In key stages of the studies leading to its approval Tecfidera was shown to reduce the number of relapses by half when compared to the placebo.
Ava Battes, Multiple Sclerosis Ireland Chief Executive, said,
"MS Ireland welcomes any new treatments for MS and with the European Commission approval of TECFIDERA in Ireland, we are delighted that it offers another treatment option to the thousands of Irish people living with the condition. It’s wonderful to see that treatment options in MS are improving all the time and this is having a real impact on improving the quality of life of people with MS.”